Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-adMSC in Traumatic Brain Injury
NCT04063215Phase 2Completed
- Sponsor
- Hope Biosciences
- Start
- Jan 2020
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic HB-adMSCs in traumatic brain injury (TBI) and hypoxic-ischemic encephalopathy (HIE), sponsored by Hope Biosciences. Primary endpoints: Vital Signs (Respiratory Rate) at 56 weeks, Vital Signs (Temperature) at 56 weeks and 5 more. Started Jan 2020; status: completed.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
traumatic brain injury (TBI)hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT04063215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063215.